Correlation between Anticonvulsant Activity and Inhibitory Action on Glial γ-Aminobutyric Acid Uptake of the Highly Selective Mouse γ-Aminobutyric Acid Transporter 1 Inhibitor 3-Hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and ItsN-Alkylated Analogs

The inhibitory effect of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole (exo-THPO) and its N-methylated (N-methyl-exo-THPO) andN-ethylated (N-ethyl-exo-THPO) analogs, derived from γ-aminobutyric acid (GABA) and 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol (THPO) on GABA transport was investigated using cultured neocortical neurons (GABA-ergic) and astrocytes and cloned mouse GABA transporters GAT1–4 expressed in human embryonic kidney (HEK) 293 cells. Anticonvulsant activity was assessed after i.c.v. administration to Frings audiogenic seizure-susceptible mice. Anticonvulsant activity of theO-pivaloyloxymethyl prodrug ofN-methyl-exo-THPO was assessed after i.p. administration. Results from these studies were compared with those obtained from similar studies with the novel anticonvulsant drug tiagabine, which acts via inhibition of GABA transport.exo-THPO and its N-alkyl analogs inhibited neuronal, astrocytic, and GAT1-mediated GABA transport but not GABA uptake mediated by GAT2–4.N-Methyl-exo-THPO was 8-fold more potent as an inhibitor of astrocytic versus neuronal GABA uptake. The IC50 value for inhibition of GABA uptake by GAT1 closely reflected its IC50 value for inhibition of neuronal uptake. Tiagabine was approximately 1000-fold more potent thanexo-THPO and its alkyl derivatives as an inhibitor of GABA uptake in cultured neural cells and GAT1-expressing HEK 293 cells.exo-THPO, its alkylated analogs, and tiagabine displayed a time- and dose-dependent inhibition of audiogenic seizures after i.c.v. administration. N-Methyl-exo-THPO was the most potent anticonvulsant among the exo-THPO compounds tested and only slightly less potent than tiagabine. The findings suggest a correlation between anticonvulsant efficacy and selective inhibition of astroglial GABA uptake. Furthermore, results obtained with the N-methyl-exo-THPO prodrug demonstrate the feasibility of developing a glial-selective GABA uptake inhibitor with systemic bioavailability.

[1]  L. Yunger,et al.  Novel inhibitors of gamma-aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. , 1984, The Journal of pharmacology and experimental therapeutics.

[2]  P. Suzdak,et al.  A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor , 1995, Epilepsia.

[3]  A. Schousboe,et al.  Uptake of GABA and nipecotic acid in astrocytes and neurons in primary cultures: Changes in the sodium coupling ratio during differentiation , 1986, Journal of neuroscience research.

[4]  A. Schousboe,et al.  Primary Cultures of Gabaergic and Glutamatergic Neurons as Model Systems to Study Neurotransmitter Functions I. Differentiated Cells , 1987 .

[5]  P. Suzdak,et al.  (R)‐N‐[4,4‐Bis(3‐Methyl‐2‐Thienyl)but‐3‐en‐1‐yl]Nipecotic Acid Binds with High Affinity to the Brain γ‐Aminobutyric Acid Uptake Carrier , 1990, Journal of neurochemistry.

[6]  A. Schousboe,et al.  Mutual Inhibition Kinetic Analysis of γ‐Aminobutyric Acid, Taurine, and β‐Alanine High‐Affinity Transport into Neurons and Astrocytes: Evidence for Similarity Between the Taurine and β‐Alanine Carriers in Both Cell Types , 1986 .

[7]  N. Nelson,et al.  A family of genes encoding neurotransmitter transporters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Schousboe,et al.  Uptake and metabolism of GABA in astrocytes cultured from dissociated mouse brain hemispheres , 1977, Neurochemical Research.

[9]  A. Schousboe,et al.  Anticonvulsant activity of the glial GABA uptake inhibitor, THAO, in chemical seizures. , 1989, European journal of pharmacology.

[10]  P. Seeburg,et al.  Transient expression shows ligand gating and allosteric potentiation of GABAA receptor subunits. , 1988, Science.

[11]  M. Orloff,et al.  Timed Intravenous Infusion of Metrazol and Strychnine for Testing Anticonvulsant Drugs.* , 1949, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[12]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[13]  A. Schousboe,et al.  Action of bicyclic isoxazole GABA analogues on GABA transporters and its relation to anticonvulsant activity. , 1999, European journal of pharmacology.

[14]  A. Schousboe,et al.  GABA uptake inhibitors: relevance to antiepileptic drug research , 1987, Epilepsy Research.

[15]  A. Schousboe,et al.  Anticonvulsant activity of the gamma-aminobutyric acid uptake inhibitor N-4,4-diphenyl-3-butenyl-4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol . , 1993, European journal of pharmacology.

[16]  Arne Schousboe,et al.  GABA transporters: functional and pharmacological properties , 2001 .

[17]  R. Mattson.  Efficacy and Adverse Effects of Established and New Antiepileptic Drugs * , 1995, Epilepsia.

[18]  B. Meldrum,et al.  Anticonvulsant profile of MDL 27,266: an orally active, broad-spectrum anticonvulsant agent , 1992, Epilepsy Research.

[19]  A. Schousboe,et al.  Tissue Distribution, Metabolism, Anticonvulsant Efficacy, and Effect on Brain Amino Acid Levels of the Glia‐Selective γ‐Aminobutyric Acid Transport Inhibitor 4,5,6,7‐Tetrahydroisoxazolo[4,5‐c]pyridin‐3‐ol in Mice and Chicks , 1986, Journal of neurochemistry.

[20]  A. Schousboe,et al.  Anticonvulsant activity of the glial-selective GABA uptake inhibitor, THPO , 1983, Neuropharmacology.

[21]  A. Schousboe,et al.  Anticonvulsant activity of intracerebroventricularly administered glial GABA uptake inhibitors and other GABAmimetics in chemical seizure models , 1989, Epilepsy Research.

[22]  P. Genton,et al.  Tiagabine in Clinical Practice , 2001, Epilepsia.

[23]  D. Thiele.  ACE1 regulates expression of the Saccharomyces cerevisiae metallothionein gene , 1988, Molecular and cellular biology.

[24]  A. Schousboe,et al.  Ontogenetic development of glutamate and GABA metabolizing enzymes in cultured cerebral cortex interneurons and in cerebral cortex in vivo , 1985, International Journal of Developmental Neuroscience.

[25]  D. Treiman.  GABAergic Mechanisms in Epilepsy , 2001, Epilepsia.

[26]  O. Devinsky.  Cognitive and Behavioral Effects of Antiepileptic Drugs , 1995, Epilepsia.

[27]  G. W. Stewart,et al.  A Modification of Davidon's Minimization Method to Accept Difference Approximations of Derivatives , 1967, JACM.

[28]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[29]  A. Schousboe,et al.  Selective inhibitors of glial GABA uptake: synthesis, absolute stereochemistry, and pharmacology of the enantiomers of 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole (exo-THPO) and analogues. , 1999, Journal of medicinal chemistry.

[30]  A. Schousboe,et al.  Transport and Metabolism of 7‐Aminobutyric Acid in Neurons and Glia: Implications for Epilepsy , 1983, Epilepsia.

[31]  Ana Gadea,et al.  Glial transporters for glutamate, glycine and GABA I. Glutamate transporters , 2001, Journal of neuroscience research.

[32]  A. Schousboe.  Pharmacological and Functional Characterization of Astrocytic GABA Transport: A Short Review , 2000, Neurochemical Research.

[33]  K. Kekesi,et al.  Differential effects of nipecotic acid and 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridin-3-ol on extracellular gamma-aminobutyrate levels in rat thalamus. , 1997, European journal of pharmacology.

[34]  T. Branchek,et al.  Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. , 1994, European journal of pharmacology.

[35]  N. Nelson,et al.  Expression of a mouse brain cDNA encoding novel gamma-aminobutyric acid transporter. , 1992, The Journal of biological chemistry.